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BACKGROUND: Central nervous system (CNS) malig-
nancies represent 20% of all childhood cancers. To
improve outcomes in infants and children with high-risk
disease, treatment can include adjuvant chemotherapy
and early autologous peripheral blood human progenitor
cell collection (AHPCC), followed by high-dose chemo-
therapy and stem cell rescue. In many protocols, post-
operative chemotherapy includes the administration of
weekly vincristine (VCR) between induction chemo-
therapy cycles, regardless of scheduled AHPCC. We
observed anecdotal AHPCC failures in children receiv-
ing midcycle VCR (MC-VCR).
STUDY DESIGN AND METHODS: The study was an
8-year retrospective chart review of all children with a
CNS malignancy and who underwent AHPCC. Informa-
tion included patient demographic and clinical data,
mobilization regimen, VCR administration, product
yields, infusion toxicity, and patient charges. Data were
analyzed relative to MC-VCR administration. Graphics
and statistical analysis (t-test, chi-square, linear regres-
sion) were performed with commercial software.
RESULTS: Twenty-four patients and 47 AHPCCs were
available for analysis. Nine patients (37%) received
MC-VCR within 7 days of scheduled AHPCC. MC-VCR
was associated with delayed marrow recovery (17.9
days vs. 14.9 days, p = 0.0012), decreased median
peripheral CD34 counts (75 × 106 CD34/L vs. 352 × 106
CD34/L, p = 0.03), decreased median CD34 yields
(2.4 × 106 CD34/L vs. 17.8 × 106 CD34/kg, p = 0.08),
more AHPCCs per mobilization (2.9 vs. 1.1, p = 0.01),
and an increased rate of remobilization (33% vs. 6%).
Mean patient charges were 2.5× higher in patients
receiving MC-VCR than controls (p = 0.01).
CONCLUSION: MC-VCR should be withheld before
scheduled AHPCC to optimize CD34 collection.
C
entral nervous system (CNS) malignancies are
the second most common cancer in children,
accounting for 20% of all childhood cancers.1
In the United States alone, there are approxi-
mately 4200 new cases diagnosed each year with the
highest incidence in children less than 5 years of age.1
Astrocytoma, primitive neuroectodermal tumors (PNETs)
including medulloblastoma, and ependymoma are the
most frequent pediatric CNS cancers, with 5-year survival
rates ranging from 40% to 80%.1-4 Poor prognostic factors
include a young age (<3-5 years), macrometastases, a
higher residual tumor burden after resection, tumor loca-
tion, unfavorable tumor histology, or genetics.2,3,5,6 Atypi-
cal teratoid rhabdoid tumors (ATRTs) have a particularly
poor prognosis, with a median survival of only 16
months.7
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Standard therapy for pediatric CNS tumors consists of
early surgical resection and radiotherapy, usually accom-
panied by adjuvant chemotherapy.2-4 Radiotherapy is the
mainstay of treatment in older children, with 55% to 80%
of medulloblastoma patients disease free after 5 years.2,8
Radiation is typically withheld, however, in very young
children (≤3 years) due to the risk of long-term, progres-
sive neuropsychiatric sequlae.2 As a consequence, adju-
vant chemotherapy has been employed to delay or avoid
radiotherapy in this population.2,4,9 Several clinical trials
have shown that most patients, regardless of age, can
benefit from adjuvant chemotherapy.2,3,8 In medulloblas-
toma, the addition of adjuvant chemotherapy has
increased the overall 5-year survival of standard risk
patients (70%-87%), infants (46%-86%), and patients with
high-risk disseminated disease (44%-60%).3 In many pro-
tocols, adjuvant chemotherapy employs several courses
of multiagent chemotherapy and weekly vincristine
(VCR).2,3,8
To further improve outcomes in infants and other
high-risk patients, more recent studies have added high-
dose, myeloablative chemotherapy and autologous stem
cell rescue.3,4,10 Patients generally undergo autologous
peripheral blood human progenitor cell collection
(AHPCC) after their first or second cycle of induction che-
motherapy, followed later by one to three cycles of high-
dose chemotherapy and stem cell rescue.10-18 Because VCR
is considered “marrow sparing” at the doses used clini-
cally,19 most protocols stipulate the continued administra-
tion of weekly VCR between induction chemotherapy
cycles (midcycle VCR [MC-VCR]), regardless of scheduled
AHPCC.12,13,15-18 We anecdotally observed several poor
AHPCC in young children who had received scheduled
MC-VCR 1 week before AHPCC. To determine whether
MC-VCR was a risk factor for poor CD34 mobilization and
collection, we performed an 8-year retrospective review of
all pediatric patients with a CNS malignancy and who
underwent AHPCC at our institution.
MATERIALS AND METHODS
Patients and study design
The study was an 8-year retrospective study of all pediatric
patients referred for AHPCC at the University of Michigan
from January 2004 through December 2011. Inclusion cri-
teria included an age less than 21 years, a histologic diag-
nosis of a CNS malignancy, and at least one AHPCC. All
clinical trial treatment protocols, AHPCCs, and data
analysis were approved by the institutional review board
of the University of Michigan.
Patient demographic data included patient age, sex,
weight, histologic diagnosis, prior therapy, mobilization
regimen, dates of VCR administration, number of mobili-
zation cycles, number of hospital days, and type of venous
access. Pharmacology data included drugs known to
decrease VCR clearance.19 Patient laboratory studies
included the preprocedure complete blood count (CBC),
white blood cell (WBC) differential, and peripheral CD34
count (%CD34, CD34 × 106/μL). For patients who received
MC-VCR, the WBC and platelet (PLT) count on the day of
VCR administration was recorded, if available. Procedure-
related information included the first day of AHPCC after
chemotherapy, the total number of AHPCCs, cell yield
(mononuclear cells [MNCs], CD34, granulocytes) per pro-
cedure, total cell yield per mobilization cycle, and need for
plerixafor salvage. For remobilized patients, each mobili-
zation cycle was counted as a separate event. Infusion
records were reviewed for patient age, weight, infusion
volume, cell dose, and adverse reactions for each infusion.
Adverse reactions were graded according to the CTC-NCI
classification.20 If more than one symptom was recorded,
the highest grade was recorded for the infusion.
Adjuvant chemotherapy
Most patients were enrolled, or treated off-study, in one of
three multi-institutional clinical trials for pediatric CNS
tumors: Children’s Oncology Group (COG)-99701, COG-
99703, and COG-ACNS0333 (Table 1).16-18 Patients treated
per COG-99701 received 6 weeks of craniospinal radiation
therapy with daily carboplatin, followed by adjuvant
therapy with cyclophosphamide, cisplatin, and VCR (Days
0 and +7). Patients treated on COG-99703 received three
cycles of induction chemotherapy with cisplatin, cyclo-
phosphamide, etoposide, and weekly VCR (Days 0, +7, and
+14) with AHPCC after their first cycle of induction che-
motherapy.17 ATRT patients enrolled in COG-ACNS0333
received three cycles of induction therapy with cyclophos-
phamide, etoposide, cisplatin, methotrexate, and weekly
VCR (Days 0, +8, and +15), with AHPCC scheduled after
their first round of induction therapy.18 VCR administered
7 to 15 days after the first day of each chemotherapy cycle
(Day 0) was classified as MC-VCR.
Three patients were treated with four to eight cycles
of cisplatin, lomustine, and weekly VCR,9 including two
patients who underwent AHPCC after eight cycles. One
patient initially treated on COG-99701 (one cycle) subse-
quently received one cycle of ifosamide, cisplatin, and
etoposide (ICE) before AHPCC.21 One patient was treated
with temozolomide.22 One patient underwent AHPCC
after receiving 8 weeks of radiation and VCR only.13
Stem cell mobilization
There were a total of 28 mobilizations in 24 patients
(Fig. 1): Four patients required remobilization due to poor
collection yields. The majority (22/24) of patients were
collected after chemotherapy and granulocyte–colony-
stimulating factor (G-CSF). Patients treated according to
COG protocols were generally collected after their first or
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second round of induction chemotherapy. Three patients
were collected after either ICE (one patient) or cyclophos-
phamide (4 gm/m2, two patients). All patients received
G-CSF (10 μg/kg) for 4 to 5 days before AHPCC. COG
patients often received low-dose G-CSF (5 μg/kg) initially,
which was increased to standard dose (10 μg/kg) after evi-
dence of marrow recovery (absolute neutrophil count
>500-1000). One MC-VCR patient with delayed marrow
recovery received a short course of high-dose G-CSF
(20 μg/kg). Plerixafor was administered to two patients
after poor collection yields on Day 1.23 Plerixafor (0.24 mg/
kg) was administered the evening before AHPCC.
Two patients were mobilized with growth factor
only. One patient received G-CSF (10-15 μg/kg), supple-
mented with plerixafor on Day 2. A second patient under-
went a remobilization with G-CSF (10 μg/kg) and
granulocyte-monocyte–colony-stimulating factor (GM-
CSF; 500 μg/kg). Because growth factor–only mobilization
is less efficient than chemotherapy mobilization, these
patients and collections were often analyzed separately
(Table 2).24,25
Leukapheresis
All patients were evaluated and medically cleared for
AHPCC according to institutional and study guidelines.
Parental consent for leukapheresis and infectious disease
testing was obtained on the first day of collection. All
patients had a preprocedure peripheral CBC and WBC dif-
ferential before each AHPCC. Most patients also had a
peripheral CD34 count drawn before the first AHPCC. The
TABLE 1. Patient demographics
Demographics All patients MC-VCR No VCR p value
Number of patients* 24* 9 16
Sex (male/female) 13/11 5/4 9/7 0.97
Age (years)† 5.4 ± 5.5 (3,0.9-19) 4.5 ± 3.5 (3, 0.9-11) 5.7 ± 6.2 (2.5, 0.9-19) 0.62
≤3 years 15* (62.5) 6* (66.7) 10* (62.5) 1.00
Weight (kg)† 23.8 ± 21.2 (15.2, 7.8-100) 19 ± 7.4 (15.6, 10-31) 26.2 ± 25.3 (14.9, 7.8-100) 0.30
Diagnosis†
Medulloblastoma 12 (50) 3 (33) 9 (56) 0.28
ATRT 6 (25) 2 (22) 4 (25) 0.88
PNET 2 (8) 1 (11) 1 (6)
Astroblastoma 1 (4) 1 (11) 0
Medulloepithelioma* 1* 1 1
Ependymoma 1 0 1
Ganglioma 1 1 0
Time from diagnosis (months)† 5.3 ± 9.1 (2.5, 0.5-44) 3.3 ± 1.6 (3.5, 1-5.7) 6.6 ± 11.5 (2, 0.5-44) 0.25
Prior radiotherapy* 11* 5 7 0.58
Carboplatin 3 2 1 0.08
Adjuvant chemotherapy
COG-99701 3 2 1 0.22
COG-99703 14 6 8‡ 0.25
COG-ACNS0333 3 0 3 0.17
Cisplatin, lomustine, VCR 3 1 2 0.92
ICE 1 0 1‡
Temozolomide 1 0 1
VCR only 1 0 1
* One patient (3 years old, medulloepithelioma) was originally collected after receiving MC-VCR. He was remobilized with cyclophosphamide
and G-CSF without additional MC-VCR. This patient also received radiation.
† Results reported as mean ± SD (median, range) or number (%).
‡ One patient was initially treated per COG-99703 (Cycle 1). Subsequent chemotherapy was changed to ICE (Cycle 2). This patient under-
went AHPCC after Cycle 2.
COG-99701 = cyclophosphamide, VCR, with or without cisplatin; COG-99703 = cisplatin, cyclophosphamide, etoposide, VCR; COG-
ACNS0333 = cisplatin, cyclophosphamide, etoposide, VCR, methotrexate; NA = not applicable.
Fig. 1. Study schematic of AHPCC and MC-VCR administra-
tion. Note that four patients required remobilization, includ-
ing three patients who initially received MC-VCR.
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need for mild sedation during AHPCC was determined by
the transplant physician. Patients who required a red
blood cell (RBC) or whole blood prime were medicated
with an antipyretic and antihistamine. RBCs were
leukoreduced before storage and irradiated per institu-
tional policy.
All patients were collected on a cell separator (COBE
Spectra, Gambro BCT, Lakewood, CO) using the WBC col-
lection set.24 Central venous catheters were used for
venous access in all patients. MNCs were collected by
continuous-flow centrifugation with a blood–plasma
interface manually adjusted to a 1% to 2% hematocrit, a
mean inlet volume of 1 mL/kg/min, and a collection
volume of 1.0 mL/min. For patients more than 10 kg,
blood was anticoagulated with ACD-A at a whole
blood : ACD-A ratio of 12 : 1. To mitigate against dilutional
anemia and hypotension, a RBC prime was used if the
extracorporeal volume was greater than 10% of the
patient’s blood volume. Patients received prophylactic
calcium gluconate to prevent citrate toxicity.
For very small children (<10 kg), AHPCC was per-
formed using a reconstituted whole blood prime and
heparin anticoagulation (30 units/kg). Heparin antico-
agulation was monitored by activated clotting time (thera-
peutic, 180-220 sec). To prevent clotting of the product,
ACD-A (10% final product volume) was manually added to
the final product.
A total of three blood volumes were processed per
AHPCC. For patients more than 40 kg, 200 mL of plasma
was collected concurrently for processing. For patients 20
to 40 kg, 100 mL of plasma was collected. No plasma was
collected for children with less than 10 kg body weight.
The desired target CD34 yield for the vast majority
(22/24) of patients was 15 million CD34/kg or sufficient
CD34 cells for three autologous hematopoietic progenitor
cell (HPC) infusions at 5 × 106 CD34/kg per infusion. The
TABLE 2. Mobilization and collection by MC-VCR administration*
Measure All patients MC-VCR No VCR p value
Number of mobilization cycles 28 11 17
Patients remobilized 4 (16) 3 (33) 1 (6) 0.08
Mobilization regimen
Chemotherapy with G-CSF 26 (93) 11 15 0.21
Treatment-specific 24 11 13 0.18
Cyclophosphamide 2 0 2 0.18
Growth factor only 2 (7) 0 2 0.21
G-CSF 1 0 1
G-CSF plus GM-CSF 1 0 1
G-CSF dose (μg/kg) 10.8 ± 2.3 9.8 ± 3.1 10.7 ± 1.9 0.65
Plerixafor salvage
Number of patients 3 2 1† 0.24
Total number of doses 9 7 2
Blood counts (Day 1)
WBC (×109/L) 19.1 ± 18 13.5 ± 21.1 22.7 ± 21.1 0.13
% MNCs 22.4 ± 15.6 27.3 ± 18.9 19.1 ± 12.5 0.19
% CD34 (median) 2.2 ± 0.6 (0.98) 2.3 ± 1.0 (0.88) 2.5 ± 0.8 (1.5) 0.90
CD34 × 106/L, ±SEM (median) 213.4 ± 61.9 (78.6) 266.3 ± 145 (74.9) 280.2 ± 58.4 (278) 0.09
Chemotherapy plus G-CSF (median) 285 ± 78.9 (222.2) 266.3 ± 145 (74.9) 331.7 ± 57.0 (352) 0.03
Growth factor only (median) 20.7 ± 10.9 (18.8) 0.004§
Collection
Day to collection‡ 16 ± 2.4 17.9 ± 2.0 14.9 ± 1.9 0.0012
Total number of procedures 47 25 22
Chemotherapy plus G-CSF 25 17
Growth factor only 0 5
Number of procedures per patient 1.9 ± 1.7 2.9 ± 2.3 1.3 ± 0.8 0.025
Chemotherapy plus G-CSF 1.8 ± 1.6 2.9 ± 2.3 1.1 ± 0.4 0.01
Growth factor only 2.5 ± 1.5 0.03§
Product yield
% MNCs 43.1 ± 20.5 39.2 ± 15 47.7 ± 25.1 0.18
MNCs × 108/kg 2.8 ± 0.3 2.5 ± 0.3 3.2 ± 0.6 0.28
% CD34 2.2 ± 0.4 1.6 ± 0.5 3.0 ± 0.5 0.06
CD34 × 106/kg (median) 16.5 ± 3.5 (4.0) 12.3 ± 5.1 (2.4) 21.0 ± 4.6 (17.8) 0.21
Chemotherapy plus G-CSF (median) 18.1 ± 3.8 (4.9) 12.3 ± 5.1 (2.4) 25.1 ± 5.2 (21.5) 0.08
Growth factor only 2.5 ± 1.3 0.004§
Total yield per mobilization
MNCs × 108/kg 4.4 ± 0.7 5.1 ± 1.3 3.2 ± 0.7 0.38
CD34 × 106/kg 30.3 ± 5.1 28.9 ± 5.3 32.7 ± 11.3 0.76
* Results reported as number (%) or mean ± SD except where noted.
† Patient mobilized with G-CSF only.
‡ Number of days since the last round of induction or mobilization chemotherapy.
§ Growth factor versus chemotherapy mobilized (no-VCR) controls.
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protocol minimum CD34 target dose was 6 million
CD34/kg or 2 × 106 CD34/kg per HPC infusion.17,18 In one
patient, the CD34 target was 8 million CD34/kg, for four
infusions at 2 × 106 CD34/kg each. One patient was col-
lected for a single autotransplant of 3 × 106 CD34/kg.24 All
patients were collected daily until they reached their CD34
target yield or unless terminated by the apheresis and
transplant physician due to poor or falling collection
yields.
Product analysis
Volume, WBC count, WBC differential (%MNCs, MNCs/
kg), and CD34 counts (%CD34, CD34/kg) were deter-
mined on all products. CD34 yields and cell viability were
determined by flow cytometry as recommended by the
International Society of Hematology and Graft Engineer-
ing (ISHAGE).26 Colony-forming assays were not per-
formed per institutional policy. Sterility testing of each
product was performed before and after processing using
the USP culture method per 21 CFR 610.12.27 Cells were
volume adjusted and divided, as appropriate, into suffi-
cient number of units to support multiple HPC rescues.
Cells were frozen in 10% dimethyl sulfoxide and stored in
the vapor phase of liquid nitrogen until use.
Cost analysis
The financial impact of MC-VCR on AHPCC costs was
performed using patient charges for leukapheresis,
cryopreservation, and need for in-patient hospitalization.
Data were limited to patients mobilized with chemo-
therapy and G-CSF. Patient charges for all services were
calculated at the 2012 fiscal year rate. Leukapheresis costs
included the technical charge for the procedure and
preprocedure laboratories (CBC, WBC differential, periph-
eral CD34 count). Cell therapy laboratory charges associ-
ated with cryopreservation included cell processing,
freezing, cell analysis (product counts, flow cytometry),
and sterility cultures. Hospital charges were based on the
daily rate for an acute care bed. For patients already hos-
pitalized for other reasons, only the days in which the
patient underwent AHPCC were included in the cost
analysis. G-CSF charges were not included due to ambigu-
ous or incomplete records from outside facilities regard-
ing the exact dates of G-CSF initiation, as well as the date
of any changes in G-CSF dosage that may have occurred
before AHPCC.17,18 Plerixafor costs were calculated using
the in-patient or direct cost rate. Because plerixafor is dis-
tributed as a single-use vial, plerixafor costs were charged
per vial regardless of the amount of plerixafor used per
injection.
Mean patient charges for leukapheresis, laboratory,
and hospitalization were analyzed relative to MC-VCR.
Because remobilization was considered a consequence
and complication of a failed initial collection series, the
additional costs of a second AHPCC series were added and
assigned to the first AHPCC (Fig. 1, n = 4). Mean patient
charges were calculated based on the sum total of all costs
divided by the number of patients. Due to the small
number of patients requiring plerixafor salvage, total
charges were calculated with and without plerixafor.
Statistical analysis
Quantitative data were reported as mean ± standard
deviation (SD) except where noted. Variables with wide
interpatient values were reported as mean, median, and
range. Quantitative data were compared relative to
MC-VCR administration by t test. Categorical data were
analyzed by chi-square using computer software (EpiInfo,
Centers for Disease Control and Prevention, Atlanta, GA).
Graphics and t tests were performed with commercial
software (Kaleidograph, Synergy Software, Reading, PA). A
p value of less than 0.05 was considered significant.
RESULTS
Patient demographics
Between 2004 and 2011, a total of 24 pediatric CNS
patients underwent AHPCC (Fig. 1). Patients ranged in age
from 10 months to 19 years of age. The majority of patients
(15/24, 62%) were 3 years or younger at time of AHPCC.
The most frequent diagnoses were medulloblastoma
(50%, Table 1), followed by ATRT and PNET. The mean
time between diagnosis and AHPCC was 5.3 months, with
85% of patients undergoing AHPCC within 6 months of
diagnosis.
All patients underwent surgical resection, followed by
chemotherapy, before referral for AHPCC. Most patients
(22/24) had received multiagent therapy with VCR,
cisplatin, cyclophosphamide, etoposide, or lomustine
(Table 1). For patients enrolled in three COG protocols,
70% underwent AHPCC after their first cycle of induction
chemotherapy. Ten patients received radiotherapy before
AHPCC.28,29 Most patients (80%) receiving radiotherapy
were more than 3 years of age (10.4 ± 4.9 years).
MC-VCR administration
VCR is administered weekly per COG-99701 (Days 0 and
+7), COG-99703 (Days 0 and +7), and COG-ACNS0333
(Days 0, +8, and +15).16-18 Nine patients received MC-VCR
within 1 week of scheduled AHPCC per protocol. Seven
patients received a single scheduled dose on Days +7 to
+8, 1 week before AHPCC. One patient received two suc-
cessive VCR doses on Days +7 and +15, with the last dose
administered the day before AHPCC. There was no signifi-
cant difference in patient age, sex, weight, diagnosis, or
prior therapy between patients who received MC-VCR and
the no-VCR cohort (Table 1).
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A CBC at the time of MC-VCR administration was
available in seven of nine patients. Three patients were
neutropenic, with a WBC count of fewer than 0.5 × 109/L
(range, 0.1 × 109-4.9 × 109/L). All patients had a PLT count
greater than 50 × 1011/L (range, 73 × 1011-169 × 1011/L). No
patient in the MC-VCR cohort received drugs known to
increase VCR toxicity.19
MC-VCR associated with delayed marrow recovery
Patients mobilized with chemotherapy and G-CSF were
tentatively scheduled for AHPCC on Day +14 after their
last round of chemotherapy. AHPCC was initiated on the
first day that the peripheral WBC count exceeded
5 × 109/L. MC-VCR patients had significantly delayed
marrow recovery (18 days vs. 15 days, p = 0.0012), with
AHPCC starting on Day +19 or later in 50% of patients
(Fig. 2A, Table 2). There was no correlation between the
peripheral WBC count at the time of
MC-VCR administration and the initia-
tion of AHPCC (R = 0.20, not shown).
Day 1 blood counts
The peripheral blood counts on the first
day of AHPCC were examined relative to
MC- VCR administration. The median
CD34 × 106/L in MC-VCR patients was
nearly fivefold lower than the no-VCR
chemotherapy controls (74.9 × 106/L vs.
352 × 106/L, Table 2), with 50% having a
peripheral CD34 count of fewer than
30 × 106/L (p = 0.01). In contrast, 90% of
chemotherapy-mobilized controls had a
peripheral CD34 count of more than
100 × 106/L on Day 1 (Fig. 2B; p = 0.07).
The lowest mean CD34 yields were
observed in patients mobilized with
growth factor only (Table 2). There
was no association between peripheral
CD34 counts and prior radiotherapy or
carboplatin administration (data not
shown).
MC-VCR associated with
more procedures
Among chemotherapy-mobilized pati-
ents, the no-VCR cohort averaged 1.1
procedures per patient (Table 2), with
almost 70% of patients successfully
collecting in one procedure (p = 0.01).
In contrast, 33% of MC-VCR patients
required four or more procedures, with
an 85% decrease in median CD34 yields
(2.4 × 106/kg vs. 21.5 × 106/kg; Table 2).
Approximately 60% (14/25) of proce-
dures yielded fewer than 3 × 106 CD34/
kg/procedure versus 12% (2/17) of chemotherapy-
mobilized, no-VCR patients (p = 0.002). Growth factor–
only mobilization was similar to MC-VCR, averaging only
2.3 × 106 CD34/kg/procedure (range, 0.7 × 106-3.9 × 106),
even after the addition of plerixafor (Table 2). There was
no significant difference in total WBC yield, %MNCs or
MNCs/kg yield per collection, or the final cell yield
(MNCs/kg, CD34/kg) per mobilization cycle. As expected,
there was a linear correlation between CD34/kg yield and
peripheral CD34 count (R = 0.81, data not shown), regard-
less of MC-VCR administration.
Mobilization failures
Four patients required remobilization. Patients receiving
MC-VCR were six times more likely to require remo-
bilization (33% vs. 5%,Table 2) and accounted for 75% of all
remobilizations. These patients were recollected after the
Fig. 2. CD34 mobilization in chemotherapy-mobilized patients by MC-VCR adminis-
tration. (A) The number of days between the last cycle of chemotherapy and AHPCC.
(B) The peripheral blood CD34 count (CD34 × 106/L) on the first-day AHPCC. Data
limited for patients mobilized with chemotherapy and G-CSF. Note, not all patients
had a Day 1 peripheral CD34 count. (■) MC-VCR; ( ) no VCR controls. (C) The
cumulative success rate per procedure24 to collect at least 6 million CD34 cells/kg or
sufficient cells for three tandem rescues at 2 × 106 CD34/kg. (D) The success rate per
procedure to collect 15 million CD34 cells/kg or sufficient cells for three tandem
rescues at 5 × 106 CD34/kg. Data limited to patients mobilized with chemotherapy
and G-CSF: growth factor–only mobilized patients were excluded. (- - -) MC-VCR;
(—) no MC-VCR controls.
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next round of protocol-specific chemotherapy with vari-
able success (Table 3). In two patients, MC-VCR was also
administered before recollection (Fig. 1; Table 3). These
two patients required daily leukapheresis for 5 consecutive
days, with a mean daily yield ranging from 1.9 to 2.2 million
CD34/kg. In contrast, withholding MC-VCR led to a highly
successful AHPCC in a third patient (37 × 106/kg).
Three patients received plerixafor.23 Two MC-VCR
patients received plerixafor for two to five procedures,
with a modest 40% improvement in CD34 yields (1.4 × 106
to 2.4 × 106/kg/procedure). Plerixafor was also adminis-
tered to a patient mobilized only with G-CSF, with a four-
fold increase in CD34 yield (0.7 × 106/kg to 3.9 × 106/kg).
Collection success rates
The cumulative success rate to collect the minimum CD34
dose (2 × 106 CD34/kg) for three tandem HPC infusions
was determined for chemotherapy-mobilized patients:
patients mobilized with growth factor only were excluded
from the analysis. In the no-VCR cohort, 80 and 93% suc-
cessfully collected at least 6 × 106 CD34/kg after one and
two AHPCCs, respectively (Fig. 2C). In MC-VCR patients,
only 55% successfully collected in one procedure and 90%
after five procedures.
Because most protocols specify an optimum CD34
dose of 5 × 106/kg per infusion, the cumulative success
rate to collect 15 million CD34/kg was also determined
(Fig. 2D). In the no-VCR group, 70% collected within two
procedures versus 44% MC-VCR patients. In three
MC-VCR patients, AHPCC was terminated at 7.5 × 106 to
10 × 106 CD34/kg due to modest collection yields, despite
remobilization (one patient) and plerixafor salvage (two
patients).
Infusion toxicity
Infusion toxicity is reported in 26% to 70% of patients
receiving cryopreserved, autologous peripheral blood
HPCs.30-33 Factors associated with infusion toxicity include
small size, multiple AHPCCs, total infusion volume,
DMSO dose, mobilization with growth factor only, and a
high prefreeze granulocyte count.24,30-33 Because most
MC-VCR patients required several AHPCCs, we reviewed
the infusion and product records of chemotherapy-
mobilized patients to determine whether MC-VCR was
associated with increased infusion toxicity.
Forty-nine infusions in 18 patients were available: six
patients did not receive autologous HPCs. Most patients
(15/18) received three tandem HPC infusions. Mild infu-
sion reactions (Grades 1-2) were documented in 45% of all
infusions and 63% of patients: no Grade 3 or 4 toxicities
were observed.20,33 Repeated infusion reactions were
observed in seven patients (7/15, 47%). There was no sig-
nificant difference in patient weight; infusion volume
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(p = 0.45); or DMSO, CD34, or MNC dose per infusion
although MC-VCR patients tended to receive more
granulocytes/kg than controls (Table 4). There was no dif-
ference in the infusion reactions between MC-VCR and
no-VCR patients (40% vs. 48%, p = 0.57).
Cost analysis in chemotherapy-mobilized patients
A comparison of patient charges relative to MC-VCR
administration was performed (Table 5). Not surprisingly,
the total mean charges for leukapheresis and cryo-
preservation in MC-VCR patients were twice those of con-
trols (p = 0.014). There was no difference in the percentage
of patients who underwent AHPCC as inpatients;
however, MC-VCR patients required more hospital
days per mobilization. Overall, MC-VCR administration
resulted in a twofold increase in mean patient charges
(p = 0.04). When the additional costs of plerixafor are
included, mean charges increased 2.5-fold, averaging
$28,000 per patient (p = 0.009). If G-CSF charges were
included, the mean cost for AHPCC in MC-VCR patients
could exceed $35,000 to $40,000.
DISCUSSION
VCR, a plant alkaloid derived from Catharanthus roseus or
Madagascar periwinkle, is a common cytotoxic agent used
in a wide range of adult and pediatric cancers.19 Mecha-
nistically, VCR binds to tubulin, leading to disruptions in
microtubule and mitotic spindle assembly, metaphase
arrest, and apoptosis. Unlike many chemotherapeutic
agents, VCR is considered marrow sparing at the doses
used clinically and is often administered as a series of
weekly infusions.19 VCR’s major side effect is neurotoxicity,
which is cumulative and dose limiting.19 Neurologic mani-
festations include a reversible peripheral neuritis that may
present as paresthesias, myalgias, lethargy, loss of deep
tendon reflexes, and neuritic pain. VCR can also result in
an autonomic neuropathy with abdominal pain, constipa-
tion, and paralytic ileus. Seizures, coma, diabetes insipi-
dus, severe marrow suppression, and death have been
reported with accidental VCR overdose.34,35 Several
drugs can potentiate VCR toxicity via inhibition of
P-glycoprotein and hepatic cytochrome P450-CYP3A4.19
VCR is a common feature in treatment protocols for
neuroblastoma and pediatric CNS tumors, which incor-
porate high-dose multiagent chemotherapy and HPC
rescue.12,13,15-18,36,37 Because VCR is considered marrow
sparing, there is no proscription against VCR administra-
tion immediately before scheduled AHPCC. However, our
data indicate that MC-VCR can adversely impact AHPCC
in many pediatric patients. Patients who received
MC-VCR within 1 week of scheduled AHPCC had signifi-
cant delays in marrow recovery, lower circulating CD34
counts, and decreased CD34 yields per procedure. As a
TABLE 4. Infusion toxicity by MC-VCR administration*
Measure All infusions MC-VCR No VCR† p value
Total number of infusions 49 20 29
Number of patients infused 18 7 11 0.81
Patient weight (kg)‡ 19.6 ± 15.8 (14) 15.0 ± 17.4 (14.1) 18.8 ± 17.4 (13.7) 0.72
Median product volume (mL)§ 100 100 100 0.46
Volume (mL/kg) 7.4 ± 3.5 7.9 ± 3.5 7.1 ± 3.5 0.45
DMSO (mL/kg) 0.73 + 0.35 0.82 + 0.41 0.69 + 0.10 0.69
CD34 (×106/kg) 8.92 + 6.23 10.46 ± 8.53 7.45 ± 3.79 0.21
MNCs (×108/kg) 1.21 ± 1.00 1.18 ± 0.75 1.01 ± 0.90 0.51
PMNs (×107/kg) 22.22 ± 17.2 27.90 ± 18.49 17.67 ± 14.9 0.05
* Results reported as mean ± SD (median).
† No-VCR cohort limited to patients mobilized with chemotherapy. Patients mobilized with growth factor only were excluded.
‡ Patient weight at time of each infusion.
§ Total PBPC volume infused per procedure.
TABLE 5. Impact of MC-VCR on patient charges*
Measure MC-VCR No VCR
Number of patients 9 15
Leukapheresis
Procedure 9,161 4,439
Laboratory 841 457
Mean charge/patient 10,002 4,897
Cell therapy laboratory
Processing 4,749 2,302
Freezing 1,328 628
Cell analysis 1,577 764
Microbiology 745 361
Mean charge/patient 8,400 4,055
Hospitalization
Number (%) of patients 7 (77.8) 10 (66.7)
Mean number of days† 3.6 1.5
Mean charge/patient† 5,158 1,732
Total mean charge/patient
Without plerixafor 23,542 10,900
With plerixafor 28,540 11,757
* Results reported in dollars, adjusted to 2012 fiscal rate. For
cost analysis, patients were assigned based on their first
AHPCC, including four patients who underwent remobilization
(see Fig. 1). Charges due to G-CSF were not included due to
incomplete data.
† Mean number of days and charges for patients who required
hospitalization.
VINCRISTINE AND HPC COLLECTION
Volume 54, August 2014 TRANSFUSION 2011
result, these patients required significantly more proce-
dures per mobilization, had higher remobilization rates,
and had significantly higher patient charges. The negative
impact of MC-VCR was starkly illustrated in three patients
who required recollection after their next round of chemo-
therapy (Table 3). Withholding MC-VCR led to a single,
high-yield AHPCC in one patient whereas multiple proce-
dures and plerixafor were necessary in two patients who
also received MC-VCR before their second AHPCC cycle.
Surprisingly, MC-VCR was not associated with an increase
in infusion toxicity, despite the increased number of pro-
cedures required in these patients.
Heavy pretreatment and radiation have both been
linked to decreased CD34 yields in children.14,15 To our
knowledge, this is the first report showing an adverse
impact by MC-VCR on CD34 collection, despite its wide-
spread use in pediatric malignancies.19 Unfortunately, few
published trials provide a detailed analysis of AHPCC in
pediatric patients. Two older studies, however, tend to
support our findings. In a neuroblastoma trial conducted
at the Children’s Memorial Hospital in Chicago, patients
received four rounds of induction chemotherapy, followed
by three mobilization cycles with cyclophosphamide and
VCR.37 As with our MC-VCR cohort, patients continued to
receive weekly VCR immediately before AHPCC. The
median CD34 yield was only 1 × 106 CD34/kg per proce-
dure, with patients requiring three to 10 procedures
(median, 6.7 procedures) to collect sufficient cells for
three HPC rescues at 2 to 3 million CD34/kg and 35%
requiring a fourth mobilization. Sung and colleagues15
reported slightly better CD34 yields in 23 pediatric CNS
tumor patients, who received weekly VCR between cycles
of conventional chemotherapy. Patients collected a
median of 9.6 × 106 CD34/kg over three procedures, or a
mean of 3.3 × 106 CD34/kg per procedure. Among patients
randomized to receive two HPC rescues, 20% (3/15) were
mobilization failures, collecting fewer than 5 × 106 C34/kg.
Three additional studies support our results in our
chemotherapy-mobilized controls, in which VCR is
administered as part of mobilization chemotherapy
without additional MC-VCR.38-40 Schroeder and cowork-
ers38 reported on 13 neuroblastoma patients who were
mobilized with cisplatin and VCR, followed by AHPCC 2
weeks later. Patients had marrow recovery by 15 days with
a mean peripheral CD34 count of 150 × 106/L and a mean
CD34 yield of 8 × 106 CD34/kg after one to two procedures.
Bensimhon and colleagues,39 in a treatment protocol for
advanced neuroblastoma, also reported good CD34 yields
after mobilization with VCR (Days 0 and +1), cyclophos-
phamide, and daunorubin. The median CD34 yields after
one to three AHPCCs ranged from 15.7 to 30.6 million
CD34/kg, depending on study cohort. Likewise, Balduzzi
and colleagues40 reported high CD34 yields after mobili-
zation with DIAVE (VCR, etoposide, idarubicin, cytosine-
arabinoside, and dexamethasone). Eighty percent of
patients successfully collected in a single procedure, with
a median peripheral CD34 count of 80 × 106 CD34/L and
median CD34 yield of 11 million CD34/kg.
Despite its reputation as marrow sparing,19 VCR is
often associated with mild to severe marrow suppression
at the doses and schedule used clinically. Zeltzer and
coworkers41 reported Grade 3 and 4 hematologic toxicity
in 40% to 50% of medulloblastoma patients receiving
standard weekly VCR. Leukopenia was the most common
toxicity, followed by moderate thrombocytopenia and
anemia. VCR appears to target colony-forming unit
(CFU)-GM while earlier pluripotent progenitors (CFU-
GEMM) appear relatively resistant.42,43 In murine models,
VCR leads to an abrupt, 70% to 80% decrease in circulating
CFUs within 24 hours that persists for several days.44 In ex
vivo purging protocols, low-dose VCR (1-3 μg/mL) was
associated with a 50% decrease in CFU-GM whereas
higher doses (100 μg/mL) resulted in 90% ablation of
CFU-GM.41,42,45,46
In summary, pediatric CNS patients receiving
MC-VCR immediately before AHPCC had delayed marrow
recovery with lower mean circulating CD34 counts and
CD34 yields. As a consequence, these patients often
required more procedures and more days of growth factor
and were at higher risk for remobilization and plerixafor
salvage. Our results are limited by the retrospective design
of the study, small patient numbers, and mix of study
patients receiving different chemotherapy and mobiliza-
tion regimens. However, the majority of patients (20/24,
Table 1) were treated per three COG studies with similar
adjuvant therapy and early AHPCCs. Since 2010, our
policy is to hold MC-VCR within 10 to 14 days before
scheduled AHPCC for all pediatric patients. Given the
widespread use of weekly VCR in pediatric malignancies,
we propose that future study protocols involving autolo-
gous HPC rescue consider withholding MC-VCR before
AHPCC.
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